Zealand Phar­ma hits ear­ly ef­fi­ca­cy goal for amylin weight loss can­di­date

Zealand Phar­ma’s amylin ana­logue weight loss can­di­date pe­tre­lin­tide helped pa­tients lose a mean 8.6% of their body weight in a Phase 1b tri­al, meet­ing ex­ec­u­tives …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.